###begin article-title 0
Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2) and gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
###xml 282 287 282 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-2</italic>
###xml 322 327 322 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-9</italic>
Matrix metalloproteinases (MMPs) are postulated to be involved in the development of retinal angiogenesis through the regulation of extracellular matrix. The objective of the present study was to test for a possible association of five single nucleotide polymorphisms (SNPs) in the MMP-2 gene and two polymorphisms in the MMP-9 gene with proliferative diabetic retinopathy (PDR) and to determine their plasma levels.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 34 46 <span type="species:ncbi:9606">participants</span>
The study comprised 490 Caucasian participants, who were divided into three groups: diabetics with PDR, diabetics without PDR, and nondiabetics. Genotypes were detected by polymerase chain reactions followed by restriction analyses with specific endonucleases and their frequencies determined. Plasma levels of MMP-2 and MMP-9 proteins were analyzed by ELISA.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-2</italic>
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-9</italic>
###xml 116 121 116 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-2</italic>
###xml 282 287 282 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-2</italic>
###xml 361 365 361 365 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">corr</sub>
Neither MMP-2 SNPs nor MMP-9 SNPs revealed significant association with PDR in single-locus comparisons; similarly, MMP-2 haplotype frequencies did not differ notably between groups, although the C-allele of the -1306C/T polymorphism and the C-allele containing haplotype (CGCG) in MMP-2 exhibited marginally significant association with PDR in males (p<0.05, pcorr=NS). Both MMP-2 and MMP-9 plasma levels showed statistically significant differences among the studied groups (p<0.001 and p=0.001, respectively) with highest levels in the PDR group. MMP-2 plasma levels were markedly higher in carriers of either the -1306CC and -1306CT genotypes and (p=0.009) or CGCG haplotype (p=0.043).
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-2</italic>
These findings indicate that genotype- and haplotype-specific effects on MMP-2 expression corresponding with its plasma levels may contribute to the susceptibility to PDR.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 169 170 169 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 404 405 404 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 406 407 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 584 585 584 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 586 587 586 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 762 763 762 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 912 913 912 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 914 915 914 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
Proliferative diabetic retinopathy (PDR) is characterized by active angiogenesis in the retina and the formation of fibrovascular tissue at the vitreoretinal interface [1]. Angiogenesis involves migration, proliferation, differentiation, and adhesion of cells and is influenced by the surrounding extracellular matrix (ECM). These processes require regulation and local production of angiogenic factors [2,3] as well as synthesis of ECM components necessary for the anchorage of migrating endothelial and other cells, such as retinal pigment epithelium, glial cells, and fibroblasts [4,5]. Degradation of ECM proteins is exerted by matrix metalloproteinases (MMPs), whose activity is, in turn, regulated by natural inhibitors known as tissue inhibitors of MMPs [6]. During angiogenesis, MMPs have an important role in connective tissue remodeling and in the degradation of basement membrane and surrounding ECM [7,8]. Thus, the regulation of angiogenesis may be dependent on the intensity of expression of these enzymes as well as endocrine and growth factors. Any genetic polymorphism in the loci encoding MMPs and their corresponding plasma levels could belong to the risk factors participating in PDR development.
###end p 11
###begin p 12
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 506 508 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
MMPs belong to a family of zinc-containing ECM-degrading enzymes that share common structural and functional properties [9]. The important molecules controlling the formation of new vessels are gelatinase A (MMP-2) and gelatinase B (MMP-9), which have the ability to cleave type IV collagen, a major component of the basement membrane. Some studies reported that both MMPs play an important role in the regulation of angiogenesis and may be relevant to the development of the proliferative phase of DR [10-12].
###end p 12
###begin p 13
###xml 205 210 205 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-2</italic>
###xml 215 220 215 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-9</italic>
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 279 284 279 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-2</italic>
###xml 362 367 362 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-9</italic>
###xml 608 613 606 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-2</italic>
###xml 707 709 705 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 739 744 737 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-9</italic>
###xml 880 882 878 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
Genetic variability in the regulatory regions of the genes is one of the significant factors that influence levels of MMPs. Several polymorphisms have been identified in the promoter and coding regions of MMP-2 and MMP-9 [13-16]. In this study, we examined five polymorphisms in MMP-2 (-168G/T, -735C/T, -790T/G, -1306C/T, and -1575G/A) and two polymorphisms in MMP-9 (-1562C/T and R279Q). We employed the following selection criteria: frequency of the minor allele >/=5%; and previous evidence that sequence variants in the promoters influence expression as well as levels of MMPs. Polymorphism -1306C/T of MMP-2 was shown to be linked to a strikingly lower promoter activity associated with the T-allele [14]. Similarly, SNP -1562C/T of MMP-9 was found to influence transcription in an allele-specific manner, the T-allele having a greater strength than the C-allelic promoter [17]. We hypothesized that susceptibility to the development of PDR may be associated with the presence of particular alleles at the MMPs loci.
###end p 13
###begin p 14
###xml 103 108 103 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-2</italic>
###xml 113 118 113 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-9</italic>
The aim of the present study was to employ PDR to find a possible association of genetic variations in MMP-2 and MMP-9. Furthermore, we determined MMP-2 and MMP-9 plasma levels in subjects studied and analyzed mutual relationships between plasma level of product and genetic variability within the particular gene.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Subjects
###end title 16
###begin p 17
###xml 900 902 894 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 112 124 <span type="species:ncbi:9606">participants</span>
###xml 337 349 <span type="species:ncbi:9606">participants</span>
###xml 474 482 <span type="species:ncbi:9606">patients</span>
###xml 487 490 <span type="species:ncbi:9606">men</span>
###xml 498 503 <span type="species:ncbi:9606">women</span>
###xml 788 796 <span type="species:ncbi:9606">patients</span>
###xml 939 947 <span type="species:ncbi:9606">patients</span>
###xml 1033 1045 <span type="species:ncbi:9606">participants</span>
###xml 1050 1053 <span type="species:ncbi:9606">men</span>
###xml 1061 1066 <span type="species:ncbi:9606">women</span>
###xml 1134 1146 <span type="species:ncbi:9606">participants</span>
###xml 1151 1154 <span type="species:ncbi:9606">men</span>
###xml 1163 1168 <span type="species:ncbi:9606">women</span>
###xml 1248 1260 <span type="species:ncbi:9606">participants</span>
###xml 1498 1509 <span type="species:ncbi:9606">participant</span>
The present study enrolled 490 unrelated Caucasian subjects, 304 of whom had type 2 diabetes mellitus (DM). All participants were divided into three groups: diabetics with PDR (PDR), diabetics without PDR (non-PDR), and nondiabetics (non-DM). DM was diagnosed previously according to the World Health Organization criteria. All diabetic participants were on some form of treatment. Mean known duration of DM was 11.4+/-0.56 years (mean+/-SE). The PDR group consisted of 129 patients (66 men and 63 women), and their average age was 62.3+/-0.72 years (range 47-79 years). All PDR subjects regularly attended a specialized diabetology unit of the Department of Ophthalmology, University Hospital Brno, Czech Republic. PDR was assessed by direct ophthalmoscopy through dilated pupils of PDR patients and classified as proliferative according to the early treatment diabetic retinopathy (ETDR) criteria [18].Ophthalmologic examinations of PDR patients were performed several times per year. The non-PDR group (n=175) was composed of 175 participants (80 men and 95 women) whose average age was 64.3+/-0.95 years. The non-DM group had 186 participants (61 men and 125 women) who had no personal history or clinical signs of diabetes. The average age of participants in this group was 59.4+/-0.99 years. Only the non-DM group (control group) had no evidence of cardiovascular disease, cancer, or allergy, and they were not taking any long-term medication. Signed informed consent was obtained from every participant in each group before their insertion in the study. The present study was conducted according to the principles of the Declaration of Helsinki and was approved by the Ethical Committee, Medical Faculty, Masaryk University, Brno, Czech Republic.
###end p 17
###begin title 18
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-2</italic>
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-9</italic>
PCR for MMP-2 and MMP-9 single nucleotide polymorphisms
###end title 18
###begin p 19
###xml 355 356 351 352 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 382 389 378 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 939 941 903 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 1133 1140 1097 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
Peripheral blood (5 ml) of all investigated subjects was obtained and mixed with EDTA. Genomic DNA was isolated from 5 ml EDTA-anticoagulated peripheral blood leukocytes by a standard extraction method and used as a template for PCR. Reactions were performed in a final volume of 25 microl, containing 50 mM KCl, 10 mM TRIS-HCl buffer, pH 8.4, 1.5 mM MgCl2, 10 pmol of each primer (Table 1), 200 microM dNTP, 1 microg of genomic DNA in the presence of 0.7 U of Taq polymerase (MBI Fermentas, Glen Burnie, MD). After the initial denaturation step (95 degreesC for 5 min), each cycle (of additional 30 cycles) consisted of a 95 degreesC denaturation for 30 s, 30 s of annealing, a 72 degreesC extension for 30 s, and a final extension lasting 8 min at 72 degreesC. Polymorphisms (-735C/T, -790T/G, -1306C/T, and -1575G/A) were genotyped by PCR and subsequent restriction with specific endonucleases according to methods described elsewhere [15]. Those polymorphisms were analyzed by the standard PCR method which was mentioned above. The primer sequences, annealing temperatures, PCR product and locations for all methods are given in Table 1. In the case of the -168G/T polymorphism, 15 mul aliquots of the PCR product were digested with 3 U of BseDI (MBI Fermentas) for 5 h at 55 degreesC. Digestion revealed fragments of 26 bp, 194 bp, and 205 bp for the wild-type allele and 26 bp and 399 bp for the mutated allele.
###end p 19
###begin title 20
PCR reaction conditions
###end title 20
###begin p 21
The table summarizes the primer sequences, annealing temperatures, and PCR product lengths.
###end p 21
###begin p 22
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-9</italic>
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
Polymorphisms -1562C/T and R279Q in MMP-9 were detected using a modified PCR method based on the published single-strand conformation polymorphism technique [16]. Aliquots (10 mul) of the -1562C/T PCR product were digested with 3 U PaeI (MBI Fermentas) for 5 h at 37 degreesC. Digestion revealed fragments of 144 and 185 bp for the mutated allele. The wild type allele C lacked the PaeI restriction site. In the case of the R279Q polymorphism, 10 mul of PCR product were digested with 3 U of SmaI (MBI Fermentas) for 5 h at 30 degreesC. Digestion revealed fragments of 22 and 73 bp for the wild type allele. The mutated allele Q lacked the SmaI restriction site.
###end p 22
###begin title 23
Determination of metalloproteinase-2 and metalloproteinase-9 plasma levels
###end title 23
###begin p 24
###xml 47 52 <span type="species:ncbi:9606">human</span>
For determination of plasma levels of MMPs the human MMP-2 and MMP-9 ELISA Kits (RayBiotech, Inc., Norcross, GA) were used according to the manufacturer's instructions. The minimum detectable dose was less than 80 pg/ml of MMP-2 and 10 pg/ml of MMP-9, respectively.
###end p 24
###begin title 25
Statistical analysis
###end title 25
###begin p 26
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
Differences in genotype distribution and consistency with Hardy-Weinberg equilibrium were tested by chi-square test. Differences in allele frequencies of SNPs were tested by two-tailed Fisher exact test. PHASE v. 2.0 [19] software was used to resolve a sample of phase-unknown multilocus genotypes and to estimate population haplotype frequencies by the Bayesian-based algorithm. Comparison of the estimated haplotype frequencies was performed as omnibus testing of differences in haplotype frequency profiles between the two groups (statistical significance assessed empirically via permutation testing). In addition, haplotype-specific effects were analyzed using inferred haplotype pairs by computing chi-square statistics.
###end p 26
###begin p 27
###xml 348 352 346 350 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">corr</sub>
Normally distributed metric parameters (Kolmogorov-Smirnov test) were presented as mean +/- standard error of the mean (SE), others as median (range). Mann-Whitney U-test, Kruskal-Wallis ANOVA and Spearman rank correlation tests were used where appropriate. Values of p<0.05 were considered to be statistically significant. Bonferroni correction (pcorr) was applied in case of multiple comparisons modifying the significant p-value threshold according to number of comparisons. Statistical analyses were performed using program package Statistica for Windows (StatSoft Inc., Tulsa, OK).
###end p 27
###begin title 28
Results
###end title 28
###begin title 29
Genetic polymorphisms of metalloproteinase-2 and metalloproteinase-9 genes and proliferative diabetic retinopathy
###end title 29
###begin p 30
###xml 141 148 141 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
Genotype frequencies of all SNPs (-168G/T, -735C/T, -790T/G, -1306C/T, â€¨-1575G/A, -1562C/T, and R279Q) in the individual groups are shown in Table 2. Genotype distribution of any of the seven polymorphism studied did not differ from Hardy-Weinberg equilibrium in any group (p>0.05). Similarly, genotype frequencies of any polymorphisms did not differ significantly between groups in pair-wise comparison (p>0.05). Comparison of allele frequencies showed statistically significant difference in allele frequencies of the -1306C/T polymorphism between the PDR versus non-DM groups (p=0.024), however, after the correction for multiple comparison the difference did not remained significant (pcorr>0.05). The calculated odds ratio (OR) for the CC and CT genotypes was 1.41 (95% confidence interval (CI): 0.52+/-3.87).
###end p 30
###begin title 31
Genotype distributions of MMP-2 and MMP-9 polymorphisms
###end title 31
###begin p 32
###xml 307 311 307 311 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">corr</sub>
There were no significant differences between the groups when comparing genotype distributions (p>0.05). The statistically significant difference was found in allele frequencies of -1306C/T polymorphism between the proliferative diabetic retinopathy (PDR versus non-diabetes mellitus (DM) groups (p=0.024; pcorr>0.05). Genotype distribution of any polymorphism did not differ from Hardy-Weinberg equilibrium in any group (p>0.05). The p-values of allele frequencies (two-tail Fisher exact test) are given in parentheses.
###end p 32
###begin p 33
###xml 139 144 139 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-2</italic>
###xml 290 297 290 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
###xml 1030 1034 1030 1034 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">corr</sub>
###xml 830 838 <span type="species:ncbi:9606">patients</span>
Testing for association carried separately for males and females revealed statistically significant gender-specific association of the two MMP-2 polymorphisms (-168G/T and -1306C/T), in particular, differences in genotype as well as in allele frequencies between the PDR and non-DM groups (Table 3). In female subjects, the significant differences in genotype distribution (p=0.040) and allele frequency (p=0.016) were found for -168G/T polymorphism. Female subjects carrying the -168T allele had a 2.45 fold higher risk of developing PDR (OR=2.45, 95% CI: 1.16-5.20) than those not carrying this allele. On the other hand, the statistically significant difference in genotype distribution (allele frequency) of -1306C/T polymorphism was found in male subjects between the same groups (p=0.039 and p=0.024). The calculated OR for patients carrying the -1306C allele was 1.88 (95% CI: 1.05-3.40). However, after taking the number of comparisons into account, we found none of the significances remained statistically significant (pcorr>0.05).
###end p 33
###begin title 34
###xml 49 54 49 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-2</italic>
Comparisons of genotype distributions of the two MMP-2 polymorphisms in male and female subjects.
###end title 34
###begin p 35
###xml 182 183 180 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 764 768 762 766 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">corr</sub>
The table shows the statistical significance of differences in allele frequencies (the p-values of two-tail Fisher exact test are given in parentheses) and genotype distribution (chi2 test) between the studied groups for the two sexes separately. In female subjects, the significant difference was found in allele frequency of the -168G/T polymorphism between the proliferative diabetic retinopathy (PDR) and non-diabetes mellitus (DM) groups (p=0.016, odds ratio (OR)=2.45, 95% CI: 1.16-5.20). In male subjects the -1306C/T polymorphism exhibited statistically significant difference in allele frequency between the same groups (p=0.024, OR=1.88 (95% CI: 1.05-3.40). However, after the correction for multiple comparisons differences were no longer significant (pcorr>0.05).
###end p 35
###begin p 36
###xml 152 157 152 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-2</italic>
###xml 1173 1180 1173 1180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4">Table 4</xref>
###xml 1943 1947 1943 1947 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">corr</sub>
###xml 616 619 <span type="species:ncbi:9606">men</span>
###xml 624 629 <span type="species:ncbi:9606">women</span>
###xml 1798 1806 <span type="species:ncbi:9606">patients</span>
Haplotype analysis was performed to compare the sum effect of genetic variability of the four polymorphisms (-1306C/T, -790T/G, -735C/T and -168G/T) in MMP-2. The -1575G/A polymorphism was omitted due to the strong linkage disequilibrium between -1306C/T and -1575G/A polymorphisms. Haplotypes were constructed from genotype data of all subjects computationally using PHASE software with the assumption of mutual independence of haplotypes. No statistically significant difference was found in haplotype frequencies between the groups studied (omnibus p>0.05; 10,000 permutations). Analyses performed separately for men and women revealed a statistically significant difference in males (omnibus p=0.042; 10,000 permutations); while no significant difference was observed in females (omnibus p=0.738, 10 000 permutations). The pair-wise comparison of groups in males showed significant differences in haplotype frequencies between PDR versus non-PDR groups (p=0.031). To analyze haplotype-specific effects on the trait (i.e., presence of PDR), we asigned pairs of haplotypes to individuals. Subsequently, numbers of individuals with this particular haplotype were counted. Table 4 shows the absolute numbers of haplotypes in particular groups that were inferred retrospectively with probability more than 90%. Carriers of haplotypes with frequencies <1% in all three groups were pooled together as "rare." Separate one-degree of freedom tests were conducted for a series of 2x2 contingency tables testing the frequency of each specific haplotype versus all others between particular groups (PDR versus non-PDR and PDR versus non-DM). Two specific haplotypes, - CGCG (OR=7.57, i.e., risk haplotype) and TGCG (OR=0.56, i.e., protective haplotype), exhibited significant associations with PDR in male patients (p=0.030 and p=0.041, respectively), after the correction for multiple tests, however, the significances did not remained significant (pcorr>0.05).
###end p 36
###begin title 37
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-2</italic>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
Haplotypes derived from MMP-2 polymorphisms in male patients
###end title 37
###begin p 38
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-2</italic>
###xml 258 259 256 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
MMP-2 haplotypes inferred from the four single nucleotide polymorphisms (SNPs; ordered from the 5' to 3'as follows: -1306C/T, -790T/G, -735C/T, and -168G/T) in males. Haplotypes with frequencies less than 1% in both groups were pooled together as "rare". chi2 (p-value) was derived from single 2x2 contingency tables testing the frequency of each specific haplotype vs. all others between particular groups (proliferative diabetic retinopathy [PDR] versus non-PDR and PDR versus non-diabetes mellitus [DM]). The double asterisk represents omnibus p-value was assessed empirically by permutation testing (PHASE output, 10 000 permutations). The asterisk means an odds ratio>1.5 was significantly associated with PDR.
###end p 38
###begin title 39
Plasma levels of metalloproteinase-2 and metalloproteinase-9 versus genetic variation
###end title 39
###begin p 40
###xml 526 531 526 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-9</italic>
MMP-9 plasma levels were 12.3 ng/ml (8.0-16.7 ng/ml) in the PDR group, 11.3 ng/ml (7.9-13.1 ng/ml) in the non-PDR group and 10.3 ng/ml (2.0-13.7 ng/ml) in the non-DM group (p=0.001, Kruskal-Wallis ANOVA). Using the Mann-Whitney U test, we observed significant differences in the plasma levels of MMP-9 between the PDR or non-PDR groups and the non-DM group (p<0.001 and p=0.006, respectively), while we observed no notable difference between the PDR and non-PDR groups (p=0.079). No significant differences were found between MMP-9 genetic variations (groups defined according to the -1562C/T or R279Q polymorphism genotypes), and plasma levels of the MMP-9 in the whole sample or within each gender and study group separately (p>0.05).
###end p 40
###begin p 41
###xml 455 460 455 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-2</italic>
###xml 787 792 787 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-2</italic>
###xml 669 677 <span type="species:ncbi:9606">patients</span>
MMP-2 plasma levels were 401.5 ng/ml (142.4-633.4 ng/ml) in the PDR group, 277.9 ng/ml (118.0-473.5 ng/ml) in the non-PDR group, and 260.8 ng/ml (44.8-428.2 ng/ml) in the non-DM group (p<0.001, Kruskal-Wallis ANOVA). The Mann-Whitney U test revealed statistically notable differences in MMP-2 between the PDR and non-PDR or non-DM groups (p=0.001 and p<0.001, respectively). A comparison of plasma levels of MMP-2 corresponding to particular genotypes of MMP-2 SNPs showed a statistically significant difference for the -1306C/T variant (p=0.011, Kruskal-Wallis ANOVA). The plasma levels were significantly higher in the CC and CT genotypes, compared to TT in diabetic patients (p=0.009, Mann-Whitney U test). No gender-specific differences were ascertained for the -1306C/T variant and MMP-2; this was mostly due to incomparably low numbers of TT genotypes after splitting the whole group into two genders.
###end p 41
###begin p 42
###xml 614 619 <span type="species:ncbi:9606">women</span>
###xml 624 627 <span type="species:ncbi:9606">men</span>
The comparison of plasma levels of MMP-2 among the haplotype groups-i.e., risk (CGCG) versus the protective (TGCG) versus all others-revealed the highest MMP-2 plasma levels were in the risk haplotype group (p=0.043, Kruskal-Wallis ANOVA). The median (range) of MMP-2 was 388.1 ng/ml (186.4-633.4 ng/ml) in the PDR-risk haplotype, 269.2 ng/ml (185.3 - 473.5 ng/ml) in the protective haplotype, and 259.5 ng/ml (44.8-425.8 ng/ml) in others, respectively. As with the previous situation, gender-specific differences were not ascertained due to low numbers of risk haplotypes after dividing the study population into women and men.
###end p 42
###begin p 43
Furthermore, because advanced age and DM duration are risk factors for PDR, we analyzed the correlation between the plasma levels of MMP-2 and MMP-9 and the aforementioned parameters. A statistically significant Spearman rank correlation was found between plasma level of MMP-2 and DM duration (Rs=0.376; p=0.005) while no other correlation was ascertained.
###end p 43
###begin title 44
Discussion
###end title 44
###begin p 45
###xml 55 60 55 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-2</italic>
###xml 65 70 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-9</italic>
###xml 232 237 232 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-2</italic>
###xml 242 247 242 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-9</italic>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
So far, no association study of genetic variability in MMP-2 and MMP-9 and PDR has been published. Retinal angiogenesis is a hallmark of PDR, involving the production of angiogenic factors as well as synthesis of ECM proteins. Both MMP-2 and MMP-9 are interesting candidate genes for PDR because of their role in connective tissue remodeling and in regulation of extracellular matrix during angiogenesis [20].
###end p 45
###begin p 46
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 596 601 596 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-2</italic>
###xml 640 642 640 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 643 645 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 944 945 941 942 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 998 1000 995 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 1137 1139 1134 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 332 344 <span type="species:ncbi:9606">participants</span>
###xml 1281 1289 <span type="species:ncbi:9606">patients</span>
Analysis of individual polymorphisms showed that their frequencies in Czech Caucasian subjects are similar to those described previously [15,21], however, none of individual polymorphism was associated with PDR in this study. Allele frequencies of the -168G/T and -1306C/T polymorphisms differed marginally in female and male study participants between the PDR and control groups; however, the interpretation of suggestive gender-specific differences is not straightforward. One possible explanation might be a different modulatory effect of sex hormones on cytokine-regulated gene expression of MMP-2 or regulation of MMP-2 plasma levels [22,23]. While single-locus association studies have prevailed in the past, haplotype-based association studies offer more robust approach to the analysis of complex traits since these studies consider the whole genetic variability within the particular locus as a unit. Previously we showed that TGF-beta1 haplotypes might play a role in PDR susceptibility [24]. Furthermore, specific haplotypes based on SNPs in the promoter region of the MMP-2 gene were associated with coronary artery disease [15]. The present study identified two specific haplotypes, CGCG (risk) and TGCG (protective), which were marginally associated with PDR in male patients. This is in agreement with the results of single-locus association since the C allele of the -1306C/T variant significantly associated with PDR in male subjects defines the two haplotypes.
###end p 46
###begin p 47
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 544 546 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 656 658 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 788 790 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 256 264 <span type="species:ncbi:9606">patients</span>
Several previous studies quantified levels of MMP-2 and MMP-9 proteins in PDR subjects [25-27]. Data were obtained by various methods (zymography, immunoblot, and immunohistochemistry), and the results showed increased concentrations of MMP-2 and MMP-9 in patients with PDR [28,29]. Using ELISA, we confirmed that PDR is associated with the highest plasma levels of both MMP-2 and MMP-9 compared to non-DM as well as non-PDR groups. Effects of genetic variability on the level of gene expression of MMPs were also described by Price and Zhang [14,17]. The transition C-->T of the -1306C/T polymorphism displayed a lower promoter activity for the T allele [17]. Furthermore, the -1575G allele increased transcription activity and had an independent additive effect with the -1306C allele [30]. Our results support an importance of the -1306C/T polymorphism as a factor determining the intermediate phenotype, since the risk CC/CT genotypes and risk haplotype containing the C allele exhibited significantly highest plasma level of MMP-2 protein. Unfortunately, we could not pursue the possible effect of male gender-specific association in the study of its effect on MMP-2 levels since the numbers were too low in some groups of genotypes or haplotypes to allow for an adequate comparison. Nevertheless, the topic is intriguing enough to warrant further study on a larger group.
###end p 47
###begin p 48
###xml 327 332 327 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-2</italic>
###xml 560 565 560 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-2</italic>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 513 520 <span type="species:ncbi:9606">patient</span>
In conclusion, we demonstrated plasma levels of MMP-2 are notably higher in patients with PDR, and they exhibit significant -1306C/T genotype- and haplotype-specific differences with higher levels in the CC/CT genotypes and CGCG haplotype. Although we have not been able to prove statistically significant association of those MMP-2 gene variants with PDR, both suggestive risk genotypes and haplotype are overrepresented in the PDR group which explains the observed difference in the MMP-2 plasma levels between patient groups. The gender-specific effects on MMP-2 regulation require further study.
###end p 48
###begin title 49
Acknowledgment
###end title 49
###begin p 50
This study was supported by grant 303/05/P523 from the Czech Science Foundation.
###end p 50
###begin title 51
References
###end title 51
###begin article-title 52
Diabetic retinopathy.
###end article-title 52
###begin article-title 53
Expression of angiogenic and fibrogenic factors in proliferative vitreoretinal disorders.
###end article-title 53
###begin article-title 54
The role of growth factors in proliferative diabetic retinopathy.
###end article-title 54
###begin article-title 55
###xml 62 69 <span type="species:ncbi:9606">persons</span>
Genetic marker associations with proliferative retinopathy in persons diagnosed with diabetes before 30 yr of age.
###end article-title 55
###begin article-title 56
The extracellular matrix of reparative tissue in the vitreous: fibronectin production in proliferative diabetic retinopathy membranes.
###end article-title 56
###begin article-title 57
Matrix metalloproteinases and tissue inhibitor of metalloproteinases: a review of their role in tumorigenesis and tissue invasion.
###end article-title 57
###begin article-title 58
Matrix integrity and the control of angiogenesis.
###end article-title 58
###begin article-title 59
Basement membrane synthesis and degradation.
###end article-title 59
###begin article-title 60
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Molecular imaging system for possible prediction of active retinopathy in patients with Diabetes mellitus.
###end article-title 60
###begin article-title 61
###xml 39 44 <span type="species:ncbi:9606">human</span>
Matrix metalloproteinase expression in human retinal microvascular cells.
###end article-title 61
###begin article-title 62
###xml 53 58 <span type="species:ncbi:9606">human</span>
Expression of Sorsby's fundus dystrophy mutations in human retinal pigment epithelial cells reduces matrix metalloproteinase inhibition and may promote angiogenesis.
###end article-title 62
###begin article-title 63
Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy.
###end article-title 63
###begin article-title 64
A polymorphism in the matrix metalloproteinase-9 promoter is associated with increased risk of preterm premature rupture of membranes in African Americans.
###end article-title 64
###begin article-title 65
###xml 60 65 <span type="species:ncbi:9606">human</span>
Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation.
###end article-title 65
###begin article-title 66
A haplotype constituted of four MMP-2 promoter polymorphisms (-1575G/A, -1306C/T, -790T/G and -735C/T) is associated with coronary triple-vessel disease.
###end article-title 66
###begin article-title 67
Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1.
###end article-title 67
###begin article-title 68
Functional polymorphism in the regulatory region of gelatinase B gene in relation severity of coronary atherosclerosis.
###end article-title 68
###begin article-title 69
Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified Airlie House classification. ETDRS report number 10.
###end article-title 69
###begin article-title 70
A new statistical method for haplotype reconstruction from population data. Comment in: Am J Hum Genet. 2001 Oct;69(4):906-14.
###end article-title 70
###begin article-title 71
A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy.
###end article-title 71
###begin article-title 72
Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease.
###end article-title 72
###begin article-title 73
###xml 136 141 <span type="species:ncbi:9606">women</span>
Effects of hormone replacement therapy on plaque stability, inflammation, and fibrinolysis in hypertensive or overweight postmenopausal women.
###end article-title 73
###begin article-title 74
Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia.
###end article-title 74
###begin article-title 75
Polymorphism R25P in the gene encoding transforming growth factor-beta (TGF-beta1) is a newly identified risk factor for proliferative diabetic retinopathy.
###end article-title 75
###begin article-title 76
###xml 55 60 <span type="species:ncbi:9606">human</span>
Characterization of an endogenous metalloproteinase in human vitreous.
###end article-title 76
###begin article-title 77
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes.
###end article-title 77
###begin article-title 78
###xml 50 55 <span type="species:ncbi:9606">human</span>
Matrix metalloproteinases and their inhibitors in human vitreous.
###end article-title 78
###begin article-title 79
###xml 29 34 <span type="species:ncbi:9606">human</span>
Matrix metalloproteinases in human diabetic and nondiabetic vitreous.
###end article-title 79
###begin article-title 80
###xml 50 58 <span type="species:ncbi:9606">patients</span>
ProMMP-9 (92 kDa gelatinase) in vitreous fluid of patients with proliferative diabetic retinopathy.
###end article-title 80
###begin article-title 81
Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness.
###end article-title 81

